Answers are grounded in this paper and cite their sources.
Objectives: Targeting drug-metabolizing enzymes in tumor cells may improve chemoprevention and chemotherapy by providing new targets for anticancer agents or combination therapies. This study investigated whether inhibition of CYP1A1, CYP3A4, and GSTP1 by α-naphthoflavone, ketoconazole, and quercetin modulates docetaxel activity in PC3 prostate cancer cells and PNT1A prostate epithelial cells. Materials and Methods: PC3 and PNT1A cells were exposed to docetaxel either alone or in combination with inhibitors of CYP1A1, CYP3A4, and GSTP1. Sub-lethal monotherapy doses were calibrated to produce approximately 70% cell viability at 24 hours and 60% at 48 hours. Cell viability was assessed by WST-1 assay, while apoptosis and necrosis were evaluated using Annexin V staining. Enzyme activities were measured by ELSA. Cellular oxidative activity was assessed by DCFDA fluorescence analysis. Results: In PC3 cells, calibrated monotherapy doses were: 4 µM docetaxel, 1000 nM α-naphthoflavone, 56.5 µM ketoconazole, and 300 µM quercetin. Combination treatments reduced cell viability by an additional 12-25% at 24 hours and by up to 45% at 48 hours, compared with docetaxel alone. Docetaxel treatment induced time-dependent changes in enzyme activities, whereas combination treatments markedly reduced DCFDA fluorescence signals. Conclusion: Co-administration of docetaxel with CYP1A1, CYP3A4, and GSTP1-related pharmacological modulators may enhance cytotoxicity in prostate cancer cells. Increased cytotoxicity was accompanied by reduced DCFDA fluorescence, indicating that enhanced treatment responses were not necessarily associated with increased oxidative fluorescence signals.
No takes yet. Share an insight, caveat, or question.
KANÇAĞI et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: